An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma



Status:Archived
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:June 2010
End Date:June 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

An Open-Label, Dose-Escalation Phase 1/1b Study of the Anti-gp75 Monoclonal Antibody IMC-20D7S In Patients With Malignant Melanoma Who Have Progressed After or During at Least One Treatment With Standard Cytotoxic Treatment or/and Immunotherapy Therapy or For Whom Standard Therapy is Not Indicated


A dose escalation study designed to determine the safety, maximum tolerated dose,
anti-melanoma activity, antibody blood levels and progression-free survival in patients with
malignant melanoma receiving IMC-20D7S either every two weeks or every three weeks.



We found this trial at
2
sites
West Virginia University Hospitals Inc.
1 Medical Center Drive
Morgantown, West Virginia 26506
304-598-4800
West Virginia University Hospitals Inc. WVU Healthcare is two corporations, University Health Associates and WVU...
2122
mi
from 91732
Morgantown, WV
Click here to add this to my saved trials
ImClone Investigational Site
Burlington, Massachusetts 01805
2570
mi
from 91732
Burlington, MA
Click here to add this to my saved trials